argenx SE (ARGX) Earnings Date & Reports

argenx reported Q4 2025 total operating income of $1.32 billion, up from $761 million in Q4 2024, driven by product net sales of $1.29 billion (74% YoY growth). This exceeded analyst consensus revenue estimates of $1.10-$1.28 billion. Full-year product net sales hit $4.15 billion, a 90% surge from $2.19 billion in 2024, far surpassing expectations around $3.58-$4.2 billion.

Diluted earnings per share (EPS) for Q4 was $8.02, beating forecasts of $5.07-$5.95 (34-42% surprise), with full-year diluted EPS at $19.57. Operating profit reached $368 million in Q4 and $1.05 billion for the year, flipping from a prior loss. Key metrics included R&D expenses of $372 million (Q4) and SG&A of $430 million, reflecting pipeline investments. No updated numerical guidance was provided, but management emphasized Vision 2030 goals.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization (market cap), technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your analysis of stocks like ARGX.

Market Reaction and Investor Sentiment

Despite strong beats, ARGX shares fell 3.1% in pre-market trading to around $792 on February 26, 2026, and declined further 5.6% the next day to $772, amid broader market weakness and profit-taking after a strong run-up. Investors appeared cautious on the premium valuation (P/E ~35) despite profitability milestone and pipeline wins, with analysts maintaining Buy ratings and raising targets (e.g., Oppenheimer to $1,060). Sentiment remains positive on VYVGART momentum but tempered by execution risks.

Forward Outlook and Key Factors to Monitor

argenx's Vision 2030 targets treating 50,000 patients, 10 labeled indications, and five Phase 3 assets by decade's end. Near-term catalysts include the PDUFA date on May 10, 2026, for VYVGART in seronegative gMG, potentially broadening its label.

Pipeline progress features topline data from ADVANCE-NEXT in primary immune thrombocytopenia (ITP) in Q4 2026, rheumatology studies (ALKIVIA for autoimmune inflammatory myopathies in Q3 2026), and empasiprubart (C2 inhibitor) in multifocal motor neuropathy (MMN) Q4 2026. Earlier assets like ARGX-121 (IgA nephropathy) and three Immunology Innovation Program (IIP) molecules enter Phase 1/2 in 2026.

Investors should track VYVGART subcutaneous (SC) prefilled syringe adoption, global patient growth beyond 19,000, and R&D expense trends amid ~$4.4 billion cash reserves. Demand in new markets (Japan, RoW) and margin expansion from scale will be key, alongside regulatory decisions in CIDP expansions.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations